N-(4-吡啶基甲基)氨基甲酸乙酯 | 102127-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-(4-吡啶基甲基)氨基甲酸乙酯
• 英文名称: ethyl N-(4-pyridylmethyl)carbamate
• 英文别名: Ethyl (pyridin-4-ylmethyl)carbamate；ethyl N-(pyridin-4-ylmethyl)carbamate
• CAS: 102127-67-3
• 化学式: C₉H₁₂N₂O₂
• mdl: MFCD01340770
• 分子量: 180.206
• InChiKey: ZCUANBZPSNQNOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-亚硝基-1-苯基-3-(4-吡啶基甲基)-脲 在 sodium hydroxide 作用下， 反应 0.17h， 生成 N-(4-吡啶基甲基)氨基甲酸乙酯
  参考文献：
  名称：

  Reactions of 1-nitroso-1-phenyl-3-(4-pyridylmethyl)ureas.

  摘要：

  将1-硝基-1-苯基和1-硝基-1-(4-甲基苯基)-3-(4-吡啶甲基)脲（Ia, b）在室温下用甲醇和乙醇处理，几乎定量产出N-(4-吡啶甲基)的甲基和乙基碳酸酯（IIIa, b），同时分别生成苯（IVa）和甲苯（IVb）。在70°C下用苯处理Ia, b，分别得到了4-吡啶甲基胺（V）和联苯（VIa）及其4-甲基衍生物（VIb）。在-5°C下用水相醋酸钠处理Ia, b，得到了1, 3-双(4-吡啶甲基)脲（VII）和苯基叠氮化物（VIIIa, b），产率超过90%。化合物Ia对大鼠腹水肝癌AH13表现出抗肿瘤活性，但对小鼠淋巴细胞白血病L1210无效。讨论了这些反应的机制以及Ia的抗肿瘤作用机制。

  DOI：

  10.1248/cpb.34.385

文献信息

• NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
  申请人：SCHERING CORPORATION

  公开号：EP0931078B1

  公开（公告）日：2006-11-15
• US5965570A
  申请人：——

  公开号：US5965570A

  公开（公告）日：1999-10-12
• US9732103B2
  申请人：——

  公开号：US9732103B2

  公开（公告）日：2017-08-15
• [EN] NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE<br/>[FR] NOUVEAUX COMPOSES TRICYCLIQUES DE PIPERIDINYLE INHIBITEURS DE LA FARNESYL-PROTEINE TRANSFERASE
  申请人：SCHERING CORPORATION

  公开号：WO1998011098A1

  公开（公告）日：1998-03-19

  (EN) Novel tricyclic compounds of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c, and d represents N or NR9, wherein R9 is O-, -CH3 or -(CH2)nCO2H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR1 or CR2; or each of a, b, c and d is independently selected from CR1 or CR2; each R1 and each R2 is independently selected from H, halo, -CR3, -OR10, -COR10, -SR10, -S(O)tR11 (wherein t is 0, 1 or 2), -SCN, -N(R10)2, -NR10R11, -NO2, -OC(O)R10, -CO2R10, -OCO2R11, -CN, -NHC(O)R10, -NHSO2R10, -CONHR10, -CONHCH2CH2OH, -NR10COOR11, -SR11C(O)OR11, -SR11N(R75)2; n is 0 (zero), 1, 2, 3, 4, 5 or 6; T is -CO-; -SO-; -SO2-; or -CR30R31-; Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR40, -SR40, -CR40R42, -NR40R42, formulae (i), (ii), (iii), (iv), (v) and (vi). Pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.(FR) L'invention porte sur de nouveaux composés tricycliques de formule (1.0) ou leur sels ou solvates pharmacocompatibles dans laquelle: l'un de a, b, c ou d représente N ou NR9 où R9 est O-, -CH3 ou -(CH2)nCO2H où n est 1 à 3, et les groupes a, b, c et d restants représentent CR1 ou CR2; ou bien chacun de a, b, c et d est sélectionné indépendamment parmi CR1 ou CR2; chaque R1 et chaque R2 est sélectionné indépendamment parmi H, halo, -CF3, -OR10, -COR10, SR10, -S(O)tR11(où t est 0, 1 ou 2), -SCN, -N(R10)2, -NR10R11, -NO2, -OC(O)R10, -CO2R10, -OCO2R11, -CN, -NHC(O)R10, -NHSO2R10, -CONHR10, -CONHCH2CH2OH, -NR10COOR11, -SR11C(O)OR11, -SR11N(R75)2; n est zéro, 1, 2, 3, 4, 5 ou 6; T est -CO-, -SO-, -SO2- ou -CR30R31-; Z représente alkyle, aryle, aralkyle, hétéroalkyle, hétéroaryle, hétéroarylalkyle, hétérocycloalkyle, hétérocycloalkylalkyle, -OR40, -SR40, -CR40R42, -NR40R42, les formules (i), (ii), (iii), (iv), (v) ou la formule (vi). L'invention porte également sur des compositions pharmaceutiques inhibitrices de la farnésyl-protéine transférase et sur un procédé d'inhibition de la fonction Ras et par là de la croissance anormale des cellules, consistant à administrer les nouveaux composés tricycliques à un système biologique. Lesdits procédés inhibent en particulier la croissance anormale des cellules, en particulier chez des mammifères tels que l'homme.
• [EN] CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS<br/>[FR] COMPOSÉS DE CARBAMATE, D'ESTER, ET DE CÉTONE POUR LE TRAITEMENT DES TROUBLES MÉDIÉS PAR LE COMPLÉMENT
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2015130830A1

  公开（公告）日：2015-09-03

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is a carbamate, ester, or ketone substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.